OTC Deficiency clinical trials at University of California Health

1 in progress, 0 open to eligible people

DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
Sorry, in progress, not accepting new patients
The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.
at UCLA

Last updated: October 7, 2025